Nuvonis Technologies GmbH

Founded

2016

Staff

6

Organization type

RDM biotech/pharma

Region

Vienna

Cluster

LISAvienna

Nuvonis is a biotech company providing innovative cell banks for vaccine and vector production. In addition, Nuvonis' experienced team provides technical support for virus production processes and vaccine strain improvement. GMP cell banks available (fully tested to ICH guidelines, serum/animal component free): # CCX.E10 and CCX.2C4, a novel avian cell line from quails # Vero cells

R&D:Our proprietary CCX cell lines from quail are designed to replace primary chicken cells and other cell types, providing an efficient platform for the production of a broad range of viral vaccines and vectors, including different strains of attenuated viruses and vectors such as NDV and VSV. These cell lines are licensed to numerous international clients in the human and veterinary vaccine industries. Our GMP Vero cell banks allow fast transition into clinical production and clinical trials.

Production:Our GMP cell banks were produced by qualified external partners, and all quality tests according to guidelines and release was performed.

Services:Based on our long experience in vaccine manufacturing and process development, we optimize and implement upstream production methods using a variety of systems (T-flasks, spinner culture, cell stacks, bioreactors and high-density bioreactor systems) on a lab scale. This includes the establishment of accurate and fast titer assays enabling efficient process optimization.

Sales/Distribution:Our GMP cell banks (Vero and avian CCX cell line) are sold based on flexible conditions for research or commercial use.